US Sen. Claire McCaskill is not done with Valeant Pharmaceuticals.
The company has been under pressure the past few weeks, first facing questions over drug pricing and then finding itself the focus of attention after short-seller Andrew Left published a report comparing it to Enron.
Valeant held an investor call Monday that was meant to address concerns over those allegations.
McCaskill, the top-ranking Democrat on the Senate’s Permanent Subcommittee on Investigations and the Senate Aging Committee, was not convinced by the call, however.
“The only thing that this morning’s investor call made clear is that Valeant’s questionable business practices extend well beyond price gouging,” McCaskillsaid in a statement.
Valeant said Monday that it would set up a committee to review business practices at Philidor, a specialty pharmacy it owns a stake in, which is at the center of fraud allegations.
Full content: Business Insider
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Business Secretary Calls for More Agile Competition Regulator
Feb 13, 2025 by
CPI
Germany’s Antitrust Regulator Raises Concerns Over Apple’s App Tracking Policies
Feb 13, 2025 by
CPI
$60 Billion Nissan-Honda Merger Falls Apart
Feb 13, 2025 by
CPI
DOJ Moves to End Protections for Three Regulatory Agencies
Feb 13, 2025 by
CPI
Meta to Allow Rivals to List Ads on Facebook Marketplace Following EU Fine
Feb 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon